Commercial-intelligence radar identifying companies likely to need Red Nucleus services, scored from public clinical-trial signals and weighted for EMEA relevance.
| Priority | Therapy Area | Phase | Presence | Top Signals | Recommended Action | ||||
|---|---|---|---|---|---|---|---|---|---|
| 97 | immediate | Arrowhead Pharmaceuticals | Cardiovascular+1 | Small | Growing | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsFDA approval | BD review now |
| 89 | high | Eli Lilly and Company | Oncology+2 | Large | Growing | Phase 3 | euusuk | Phase 3 readout within 12 monthsPhase 3 trial activeRevenue growth | Trigger deep research |
| 88 | high | Gilead Sciences | Cardiovascular+1 | Mid | Growing | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsRevenue growth | Trigger deep research |
| 88 | high | Lexicon Pharmaceuticals | Cardiovascular | Small | Growing | Phase 3 | euusuk | Phase 3 readout within 12 monthsPhase 3 trial activeRevenue growth | Trigger deep research |
| 87 | high | REGENXBIO Inc. | Rare Disease+1 | Small | Growing | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsRevenue growth | Trigger deep research |
| 86 | high | Alnylam Pharmaceuticals | Cardiovascular+1 | Mid | Growing | Phase 3 | euusuk | Phase 3 trial activeRevenue growthPhase 2 trial active | Trigger deep research |
| 86 | high | AstraZeneca RN client | Cardiovascular+3 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsFDA approval | Trigger deep research |
| 86 | high | Kite, A Gilead Company | Oncology | Mid | Growing | Phase 3 | euusuk | Phase 3 trial activeRevenue growthPhase 2 trial active | Trigger deep research |
| 85 | high | AbbVie (prior sponsor, Abbott) | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activeFDA approvalPhase 2 trial active | Trigger deep research |
| 85 | high | Astellas Pharma Inc | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activeFDA approvalPhase 2 trial active | Trigger deep research |
| 85 | high | Boehringer Ingelheim | Cardiovascular+1 | — | — | Phase 3 | euusuk | Phase 3 trial activeFDA approvalMultiple active trials | Trigger deep research |
| 85 | high | Bristol-Myers Squibb | Oncology+1 | Large | Stable | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsFDA approval | Trigger deep research |
| 85 | high | GlaxoSmithKline | Oncology+2 | — | — | Phase 3 | euusuk | Phase 3 trial activeFDA approvalMultiple active trials | Trigger deep research |
| 84 | high | Novartis Pharmaceuticals | Cardiovascular+2 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsFDA approval | Trigger deep research |
| 84 | high | Pfizer | Oncology+3 | Large | Stable | Phase 3 | euusuk | Phase 3 trial activeFDA approvalMultiple active trials | Trigger deep research |
| 83 | high | Celgene | Oncology+1 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsPhase 2 trial active | Trigger deep research |
| 83 | high | Daiichi Sankyo | Oncology+1 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsPhase 2 trial active | Trigger deep research |
| 83 | high | Novo Nordisk A/S | Obesity / GLP-1 / Cardiometabolic+1 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsPhase 2 trial active | Trigger deep research |
| 82 | high | Cytokinetics | Cardiovascular | Small | Contracting | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsFDA approval | Trigger deep research |
| 82 | high | Regeneron Pharmaceuticals | Cardiovascular+1 | Mid | Growing | Phase 3 | euusuk | FDA approvalRevenue growthPhase 2 trial active | Trigger deep research |
| 81 | high | Bayer | Oncology+1 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsPhase 2 trial active | Trigger deep research |
| 81 | high | Genmab | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsMultiple active trials | Trigger deep research |
| 80 | high | Intellia Therapeutics | Cardiovascular | Small | Growing | Phase 3 | euusuk | Phase 3 trial activeRevenue growthEU clinical trial sites | Trigger deep research |
| 80 | high | Merck Sharp & Dohme LLC | Cardiovascular+1 | Large | Stable | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsMultiple active trials | Trigger deep research |
| 78 | monitor | Autolus Limited | Oncology+1 | Small | Growing | Phase 2 | euusuk | Revenue growthMultiple active trialsPhase 2 trial active | Add to watchlist |
| 78 | monitor | Taiho Oncology, Inc. | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activeMultiple active trialsPhase 2 trial active | Add to watchlist |
| 77 | monitor | Ionis Pharmaceuticals, Inc. | Cardiovascular | Small | Contracting | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsPhase 2 trial active | Add to watchlist |
| 76 | monitor | Alexion Pharmaceuticals, Inc. | Cardiovascular | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Add to watchlist |
| 76 | monitor | BioNTech SE | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Add to watchlist |
| 76 | monitor | Eidos Therapeutics, a BridgeBio company | Cardiovascular | — | — | Phase 3 | euusuk | Phase 3 trial activeMultiple active trialsPhase 2 trial active | Add to watchlist |
| 76 | monitor | EMD Serono Research & Development Institute, Inc. | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Add to watchlist |
| 76 | monitor | Janssen Research & Development, LLC | Cardiovascular+2 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Add to watchlist |
| 75 | monitor | Biogen | Cardiovascular | Mid | Stable | Phase 3 | euusuk | Phase 3 trial activeEU clinical trial sitesTrial has both US and EU sites | Add to watchlist |
| 74 | monitor | NewAmsterdam Pharma | Cardiovascular | Small | Contracting | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsEU clinical trial sites | Add to watchlist |
| 73 | monitor | Lakefront Biotherapeutics NV | Oncology+1 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Add to watchlist |
| 72 | monitor | ArriVent BioPharma, Inc. | Oncology | — | — | Phase 3 | euusuk | Phase 3 trial activeEU clinical trial sitesUK clinical trial sites | Add to watchlist |
| 72 | monitor | Hoffmann-La Roche | Oncology+1 | — | — | Phase 3 | euusuk | Phase 2 trial activeMultiple active trialsEU clinical trial sites | Add to watchlist |
| 72 | monitor | Sarepta Therapeutics, Inc. | Rare Disease | Small | Contracting | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsEU clinical trial sites | Add to watchlist |
| 70 | monitor | MediLink Therapeutics (Suzhou) Co., Ltd. | Oncology | — | — | Phase 2 | euusuk | Phase 2 trial activeMultiple active trialsUK clinical trial sites | Add to watchlist |
| 70 | monitor | Rhythm Pharmaceuticals, Inc. | Obesity / GLP-1 / Cardiometabolic | — | — | Phase 3 | euusuk | Phase 3 trial activeEU clinical trial sitesMultiple indications | Add to watchlist |
| 68 | low | Assistance Publique - Hôpitaux de Paris | Cardiovascular+2 | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Store / low priority |
| 66 | low | Hospices Civils de Lyon | Rare Disease+2 | — | — | Phase 3 | euusuk | Phase 3 trial activeMultiple active trialsPhase 2 trial active | Store / low priority |
| 66 | low | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Other | Large | Stable | Phase 3 | euusuk | Phase 3 trial activePhase 2 trial activeMultiple active trials | Store / low priority |
| 66 | low | Kardigan, Inc. | Cardiovascular | — | — | Phase 3 | euusuk | Phase 3 trial activeEU clinical trial sitesUK clinical trial sites | Store / low priority |
| 66 | low | Takeda | Cardiovascular+1 | — | — | Phase 3 | euusuk | Phase 2 trial activeEU clinical trial sitesUK clinical trial sites | Store / low priority |
| 65 | low | Gustave Roussy, Cancer Campus, Grand Paris | Oncology | — | — | Phase 3 | euusuk | Phase 2 trial activeMultiple active trialsEU clinical trial sites | Store / low priority |
| 64 | low | Alentis Therapeutics AG | Oncology | — | — | Phase 2 | euusuk | Phase 2 trial activeMultiple active trialsMultiple indications | Store / low priority |
| 64 | low | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Oncology+1 | — | — | Phase 3 | euusuk | Phase 3 readout within 12 monthsPhase 3 trial activePhase 2 trial active | Store / low priority |
| 64 | low | Eisai Inc. | Obesity / GLP-1 / Cardiometabolic+1 | — | — | Phase 3 | euusuk | Phase 2 trial activeTrial has both US and EU sitesEU clinical trial sites | Store / low priority |
| 64 | low | Hamilton Health Sciences Corporation | Cardiovascular | — | — | Phase 3 | euusuk | Phase 3 trial activePhase 3 readout within 12 monthsPhase 2 trial active | Store / low priority |